Back

Short and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation

27 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Heart disease in the elderly: treatment and outcomes Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Giuseppe Armentaro

University Hospital Renato Dulbecco, Catanzaro (Italy)

6 More presentations in this session

Presentation thumbnail
Potential cardioprotective effects of acetylcholinesterase inhibitors in patients with Alzheimer's disease
Doctor L. Rampa (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Age disparity among severe aortic stenosis patients: AVR treatment rates and clinical outcomes among octogenarians
Mr O. Shimoni (IL)
Abstract Slides Video
Presentation thumbnail
Outcomes of catheter ablation for ventricular tachycardia in the geriatric population
Doctor G. Kowlgi (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Adverse cardiovascular outcomes and sex-specific differences among older adults with cardiac ageing
Associate Professor R. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Long-term prognosis of elderly patients undergoing atrial septum defect closure: are we acting too late?
Doctor M. Lima (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Heart disease in the elderly: treatment and outcomes

The Event

Event poster

ESC Congress 2023

27 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Clinical impact of renal function changes in patients with atrial fibrillation receiving anticoagulation with marginal renal function
thumbnail
Congress Presentation
Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants
thumbnail
Congress Presentation
Implications of renal function on adverse clinical events in patients with atrial fibrillation: a comparative analysis of VKA and NOAC therapy - Insights from the GLORIA-AF Registry Phase III

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources